利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.05 秒)

    Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer
    34.
    发明授权
    Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer 有权
    树突状细胞疫苗含有端粒酶逆转录酶用于治疗癌症

    公开(公告)号：US06440735B1

    公开(公告)日：2002-08-27

    申请号：US09675321

    申请日：2000-09-28

    申请人： Federico C. A. Gaeta

    发明人： Federico C. A. Gaeta

    IPC分类号： C12N508

    CPC分类号： C12N9/1241 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55522 ,  C12N9/1276

    摘要： The invention provides a method of activating a T lymphocyte by contacting the T lymphocyte with a dendritic cell (DC) that presents a telomerase reverse transcriptase (TRT) peptide in the context of a MHC class I or MHC class II molecule. The DC may be pulsed with a TRT polypeptide or may comprise a recombinant polynucleotide encoding a TRT such as hTRT. The invention also provides DCs comprising a recombinant TRT polynucleotide. The methods and compositions of the invention are used in prevention and treatment of cancers and other cell proliferation diseases or conditions.

    摘要翻译： 本发明提供了通过使T淋巴细胞与MHC I类或II类分子的上下文中呈递端粒酶逆转录酶（TRT）肽的树突状细胞（DC）接触来激活T淋巴细胞的方法。 DC可以用TRT多肽脉冲，或者可以包含编码TRT的重组多核苷酸，例如hTRT。 本发明还提供了包含重组TRT多核苷酸的DC。 本发明的方法和组合物用于预防和治疗癌症和其它细胞增殖疾病或病症。

    Bivalent sialyl X saccharides
    38.
    发明授权
    Bivalent sialyl X saccharides 失效
    二价唾液酸X糖

    公开(公告)号：US5559103A

    公开(公告)日：1996-09-24

    申请号：US278020

    申请日：1994-07-20

    申请人： Federico C. A. Gaeta ,  Shawn A. DeFrees

    发明人： Federico C. A. Gaeta ,  Shawn A. DeFrees

    IPC分类号： A61K31/715 ,  A61P43/00 ,  C07H3/06 ,  C08B37/00 ,  A61K31/725

    CPC分类号： C07H3/06 ,  Y10S514/886 ,  Y10S514/887

    摘要： The present invention relates to bivalent sialyl Lewis X saccharide compounds that inhibit cellular binding to a selectin receptor. Pharmaceutical compositions containing a compound of Formula I, and processes for making and using the same are disclosed. A contemplated bivalent sialyl Lewis X saccharide compound has a structure that corresponds to Formula I, below, ##STR1## wherein R is a directly linked divalent monosaccharide unit; Y is selected from the group consisting of C(O), SO.sub.2, HNC(O), OC(O) and SC(O);R.sup.2 is selected from the group consisting of a C.sub.1 -C.sub.6 hydrocarbyl, an aryl, a substituted aryl and a phenyl C.sub.1 -C.sub.3 alkylene group, wherein an aryl group has one six-membered aromatic ring or two fused six-membered aromatic rings, which ring or rings are hydrocarbyl, monoazahydrocarbyl, or diazahydrocarbyl rings, and a substituted aryl group is a before-mentioned aryl group having a substituent selected from the group consisting of halo, trifluoromethyl, nitro, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, benzylamino and C.sub.1 -C.sub.6 alkylbenzylamino;R.sup.3 is methyl or hydroxymethyl;X is selected from the group consisting of hydroxyl, C.sub.1 -C.sub.6 acyloxy, C.sub.2 -C.sub.6 hydroxylacyloxy, halo and azido;Z.sup.1 and Z.sup.2 are .alpha.-L-fucosyl or hydrogen (H), but at least one of Z.sup.1 and Z.sup.2 is .alpha.-L-fucosyl; andM is a proton (H.sup.+) or a pharmaceutically acceptable cation.

    摘要翻译： 本发明涉及抑制细胞与选择蛋白受体结合的二价唾液酸路易斯X糖化合物。 公开了含有式I化合物的药物组合物及其制备和使用方法。 预期的二价唾液酸路易斯X糖化合物具有对应于下式I的结构，其中R是直接键合的二价单糖单元; Y选自C（O），SO 2，HNC（O），OC（O）和SC（O））。 R2选自C1-C6烃基，芳基，取代芳基和苯基C1-C3亚烷基，其中芳基具有一个六元芳环或两个稠合六元芳环，其中 环或环是烃基，单肼基或二氮杂烃环，取代的芳基是具有选自卤素，三氟甲基，硝基，C 1 -C 6烷基，C 1 -C 6烷氧基，氨基 ，单-C 1 -C 6烷基氨基，二-C 1 -C 6烷基氨基，苄基氨基和C 1 -C 6烷基苄基氨基; R3是甲基或羟甲基; X选自羟基，C 1 -C 6酰氧基，C 2 -C 6羟基酰氧基，卤素和叠氮基; Z1和Z2是α-L-岩藻糖基或氢（H），但Z1和Z2中的至少一个是α-L-岩藻糖基; 并且M是质子（H +）或药学上可接受的阳离子。